4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 20, 2010, Pages 6096-6099

  Liu, Kevin K C ^a   Bagrodia, Shubha ^a   Bailey, Simon ^a   Cheng, Hengmiao ^a   Chen, Hui ^a   Gao, Lisa ^a   Greasley, Samantha ^a   Hoffman, Jacqui E ^a   Hu, Qiyue ^a   Johnson, Ted O ^a   Knighton, Dan ^a   Liu, Zhengyu ^a   Marx, Matthew A ^a   Nambu, Mitchell D ^a   Ninkovic, Sacha ^a   Pascual, Bernadette ^a   Rafidi, Kristina ^a   Rodgers, Caroline M L ^a   Smith, Graham L ^a   Sun, Shaoxian ^a   Wang, Haitao ^a   Yang, Anle ^a   Yuan, Jing ^a   Zou, Aihua ^a   more..

^a PFIZER INC   (United States)

Author keywords

Cancer; Kinase inhibitor; mTOR; PI3K

Indexed keywords

4 METHYLPTERIDINONE; ADENOSINE TRIPHOSPHATE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; DRUG SELECTIVITY; DRUG SOLUBILITY; HUMAN; IN VIVO STUDY; MOLECULAR MODEL; ORAL DRUG ADMINISTRATION; TUMOR GROWTH;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GLIOMA; HUMANS; MICE; MODELS, MOLECULAR; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PTERIDINES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TOR SERINE-THREONINE KINASES;

EID: 77956939303     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.08.045     Document Type: Article

References (11)

1. J.A. Engelman, J. Luo, and L.C. Cantley Nat. Rev. Genet. 7 2006 606
2. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Science 307 2005 1098
3. D.K. Broderick, D. Chunhui, T.J. Parrett, Y.R. Samuels, J.M. Cummins, R.E. McLendon, D.W. Fults, V.E. Velculescu, D.D. Bigner, and H. Yan Cancer Res. 64 2004 5048
4. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S.M. Powell, G.J. Riggins, J.K.V. Willson, M. Sanford, K.W. Kinzler, V. Bert, and V.E. Velculescu Science 324 2004 554
5. S. Huang, and P.J. Houghton Curr. Opin. Pharmacol. 3 2003 371
6. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawaska, J. Sosman, D. McDermott, and L. Bodrogi N. Engl. J. Med. 356 2007 2271
7. D.D. Sarbassov, S.M. Ali, and D.M. Sabatini Curr. Opin. Cell Biol. 17 2005 596
8. Cheng, H.; Bhumralkar, D.; Dress, K.; Hoffman, J. E.; Johnson, M. C.; Kania, R. S.; Le, P. T. Q.; Nambu, M. D.; Pairish, M. A.; Plewe, M. B.; Tran, K. T. 2008, WO 2008032162.
9. Bruendl, M. M.; Gogliotti, R. D.; Goodman, A. P.; Reichard, G. 2005 WO 2005105801.
10. We cannot get PI3Kα co-crystal structures so we used PI3Kγ enzyme instead of PI3Kα enzyme for our dual inhibitor program.
11. A review on Suzuki-Miyaura reaction: N. Miyaura, and A. Suzuki Chem. Rev. 95 1995 2457